beta

TNDM

Tandem Diabetes Care, Inc.

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.

Market Cap: 3.66 Billion

Primary Exchange: NASDAQ

Website: http://www.tandemdiabetes.com

Shares Outstanding: 59.7 Million

Float: 56.7 Million

Dividend: (%)

Beta: 1.00302531539193

Sector: Health Technology

Industry: Medical Specialties

Ethical Flags

Longest drawdown: 1797 trading days

From: 2014-01-10 To: 2020-04-03

Lowest Point:

Tandem Diabetes: ADA Presentations Reaffirm Control-IQ Excellent Performance

via: SeekingAlpha at 2019-06-11 03:46:36:000

Data presented by two studies, one NIH funded and one performed in France, supported the safety and efficacy of the Tandem ( TNDM ) t:slim X2 with Control-IQ. In a 6 month study in adults, when compared with sensor-augmented pump therapy, Control-IQ demonstrated better time in target range, … read more...

Tandem Diabetes: ADA Presentations Reaffirm Control-IQ Excellent Performance

via: SeekingAlpha at 2019-06-11 03:46:36:000

Data presented by two studies, one NIH funded and one performed in France, supported the safety and efficacy of the Tandem ( TNDM ) t:slim X2 with Control-IQ. In a 6 month study in adults, when compared with sensor-augmented pump therapy, Control-IQ demonstrated better time in target range, … read more...

Tandem Diabetes: ADA Presentations Reaffirm Control-IQ Excellent Performance

via: SeekingAlpha at 2019-06-11 03:46:36:000

Data presented by two studies, one NIH funded and one performed in France, supported the safety and efficacy of the Tandem ( TNDM ) t:slim X2 with Control-IQ. In a 6 month study in adults, when compared with sensor-augmented pump therapy, Control-IQ demonstrated better time in target range, … read more...

Insulet's closed-loop insulin pump shows positive effect in T1D study; shares up 2%

via: SeekingAlpha at 2019-06-10 09:22:08:000

Insulet ( PODD +2.3% ) is up on below-average volume on the heels of positive results from a study evaluating Omnipod Horizon, its hybrid closed-loop system, for glycemic control in children as young as two old with type 1 diabetes (T1D). The data were presented at the American Diabetes … read more...

Tandem Diabetes down 6% on despite positive insulin pump data

via: SeekingAlpha at 2019-06-10 07:19:41:000

Tandem Diabetes Care ( TNDM -6.3% ) slumps on almost 40% higher volume following its announcement of results from two studies of its t:slim X2 insulin pump with software called Control-IQ which automatically adjusts insulin delivery based on continuous glucose measurements (closed loop m… read more...

Tandem Diabetes Care Reports Positive Results From Two Studies of the t:slim X2 Insulin Pump With Control-IQ Technology

via: Business Wire at 2019-06-09 14:30:00:000

Significant Time-in-Range Improvements Demonstrated in Adult and Pediatric Age Groups Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced positive results from two studies of the t:slim X2 insulin pump with Con… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
2017-10-10 10.0 1.0 10.0
Data provided by IEX Cloud